Form Type: 4

Accession Number:	0001209191-21-007028
Date:	2021-01-31
Issuer:	TRAVERE THERAPEUTICS, INC. (TVTX)
Original Submission Date:

Reporting Person:

ROTE WILLIAM E.
C/O TRAVERE THERAPEUTICS, INC.
3611 VALLEY CENTRE DRIVE, STE 300 SAN DIEGO, CA 92130

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of Security	Transaction Date	2a. Deemed Execution Date	Transaction Code	Shares	Acquired or Disposed	Price per share	5. Amount of Securities Beneficially Owned Following Reported Transaction	6. Ownership Form Direct or Indirect	Nature of Indirect Ownership
COMMON STOCK	2021-01-31		A	5,000	a	$0.00	44,582	direct
COMMON STOCK	2021-02-02		S	2,500	d	$30.75	40,957	direct
COMMON STOCK	2021-02-02		S	1,125	d	$30.75	43,457	direct

Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security	Conversion or Exercise Price of Derivative Security	Transaction Date	Deemed Execution Date	Transaction Code	Number of Derivative Securities Acquired (A) or Disposed of (D)	Date Exercisable	Expiration Date	Title and Amount of Securities Underlying Derivative Security	Price of Derivative Security	Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I)	Nature of Indirect Beneficial Ownership

Footnotes
ID	footnote
f1	on january 31, 2020, the reporting person was granted a performance restricted stock unit (prsu) grant covering 10,000 shares of the issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. on january 31, 2021, a portion of the prsus vested upon the 12 month anniversary of the date of grant, following the issuer's prior confirmation of the satisfaction of a performance criterion related to the full enrollment of the duplex study.
f2	the sales reported in this form 4 were made pursuant to a written plan meeting the requirements of rule 10b5-1(c) of the securities exchange act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.
f3	the sales reported in this form 4 were made pursuant to a written plan meeting the requirements of rule 10b5-1(c) of the securities exchange act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

Elevate your investments